Market Entry - Biomanufacturing Market in Israel: Analysis of Growth, Trends and Progress (2020 - 2025)

About the Market

Biologic-baseddrugs are an increasingly important part of product growth strategies for pharmaceutical and biopharmaceutical companies. Biopharmaceutical products have rapidly taken over pharmaceutical company revenues, with sales of the top six antibody products viz., Humira, Remicade, Enbrel, Rituxan, Avastin, Herceptin, at just over USD 51 billion in 2015. 77% of over 900 biopharmaceutical products are produced in mammalian cell culture systems in the United States and Europe. In terms of production capacity, North America holds the greatest at 52%, followed by Europe and Asia. Due to government incentives in tax reforms, favorable locations with mature pipelines, and the ability to manage complex global supply chains, Asia has significant growth capacity. Samsung, Bristol-Myers Squibb, and Novartis are some of the key players in the market.

About the Geography

Israel is a small country located in the Middle East bordered by Egypt, Jordan, Lebanon, and Syria. Israel has a liberal investment system and most activities are open to both private nationals and foreign investors. It has many tech start-ups, funded by America, a strong R7D sector, and a highly skilled multi-lingual workforce.

The government encourages entrepreneurship and the country is the second largest regarding the availability of venture capital. The recent revision of Encouragement of Capital Investments Law now includes financial incentives for foreign investments. Israel is bordered by countries with on-going wars and terrorist activities, which act as a major impediment for foreign investors. It also has high corporate taxes and cost of manpower.

Israel invests almost 5% of its GDP in R&D and has many highly qualified engineers with access to funds. For these reasons, Israel is a good country to invest in if a company wants to set up an R&D wing, branch office, or LLC.

The Market Entry Series

Exploring global markets is now recognized as the shortest way to ensure high time to efficiency conversion, when trying to expand revenues past domestic markets, for firms both large and small. Our market entry series, priced suitably low contains the essentials of all the parameters (Refer: Table of Contents) you must be apprised of before you can have a well informed contemplation of a business opportunity in your choice of industry, in your choice of geography.